CD274 and non-small cell lung carcinoma: In comparison to other real-world data, a systematic review conducted a head-to-head comparison between nivolumab plus ipilimumab and pembrolizumab as first-line chemotherapy-free treatments for PD-L1-positive non-small cell lung cancer [40].